-
How difficult is it to get a generic drug for Seretide on the market?
Time of Update: 2021-04-23
Recently, Hengrui issued an announcement stating that, in accordance with the latest policy of the State Food and Drug Administration on drug review and approval, combined with the company's actual situation, it has submitted to the State Food and Drug Administration an application for withdrawal of salmeterol ticasone powder inhalation drug registration.
-
The drug dealer issued a notice: a "4+7" quantity-collected product, difficult to purchase
Time of Update: 2021-04-23
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
-
State Council: Let go of the prescription drug sales online!
Time of Update: 2021-04-23
(Ministry of Civil Affairs, National Health Commission, State Drug Administration and other relevant departments of the State Council and various regions are responsible according to the division of responsibilities) Among them, “on the premise of ensuring the authenticity and reliability of the source of electronic prescriptions, online sales of prescription drugs other than those under special state management are allowed.
-
The licensed pharmacist country has begun to issue subsidies
Time of Update: 2021-04-23
The announcement showed that, in accordance with the spirit of the relevant documents, the Baoji City Social Insurance Management Center approved the grant of technical skill improvement subsidies to 442 employees of enterprises and institutions including Zhang Hua.
-
Yuheng Pharmaceutical's Lugua Polypeptide was withdrawn from the Internet!
Time of Update: 2021-04-23
According to the requirements of the notice, since the date when the provincial medicine price and credit evaluation system for recruitment and procurement takes effect, pharmaceutical companies participating in or entrusting to participate in centralized procurement, online procurement, and filing procurement of drugs and medical consumables must submit a trustworthy commitment.
-
"Barrier Free" Circulation in the Medical Union!
Time of Update: 2021-04-23
The document clearly stated that for traditional Chinese medicine preparations with definite curative effect, reliable quality, approved documents, still within the validity period, and clinically safe use for more than 2 years, "barrier-free" adjustments and use in the provincial medical association are allowed.
-
Kangmei Pharmaceuticals exploded again!
Time of Update: 2021-04-23
Kangmei Pharmaceutical was listed on the Shanghai Stock Exchange in 2001, with a listed market value of less than 900 million.
-
Yangzijiang Pharmaceutical was fined 764 million yuan for implementing the monopoly agreement!
Time of Update: 2021-04-23
The above-mentioned actions of Yangtze River Pharmaceutical Group have eliminated and restricted competition, harmed the legitimate rights and interests of consumers and the public interest, and violated Article 14 of the Anti-Monopoly Law, which prohibits operators and counterparties from reaching the following monopoly agreements: (1) Fixed The price for resale of commodities to third parties; (2) The provisions of limiting the minimum price for reselling commodities to third parties.
-
Announcement of annual results of Machinery Enterprise: Weigao, MicroPort, Yuyue...
Time of Update: 2021-04-23
2500%， ，iFinD，412，332020。 ，，2020，。 ，、，202047. 63，1203. 53%；26. 17，6527. 90%。 ，、、。 2020138. 37，564. 29%；70. 07，3829. 56%。，。 Previously, in the 2020 annual report performance forecast disclosed
-
AstraZeneca's diabetes drug Farxiga fails in COVID-19 study
Time of Update: 2021-04-23
Compile Ke KeOn April 12, AstraZeneca announced that its diabetes drug Farxiga (dapagliflozin) failed to reach the end point in a phase three study.
The DARE-19 study provides important data on the potential benefits and risks of using SGLT2 inhibitors to treat COVID-19 hospitalized patients.
-
License-in inventory for the first quarter!
Time of Update: 2021-04-23
Introduced party: Sidi MedicineAuthorized party: ImmuneOncia TherapeuticsMechanism of drug action: anti-CD47 monoclonal antibodyOn March 31st, Sidi Medicine announced that it has obtained the exclusive authorization for the development, production and commercialization of ImmuneOncia's new generation of anti-CD47 monoclonal antibody IMC-002 tumor indications in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
-
National Food and Drug Administration: Guifu Dihuang Granules converted to non-prescription drugs
Time of Update: 2021-04-23
This product contains aconite (made)[Drug Name]Generic name: Guifu Dihuang GranulesChinese Pinyin:[Ingredients][Properties][Functions and Indications] Warming and nourishing kidney-yang.
If you are using other drugs, please consult your physician or pharmacist before using this product.
-
Yuandong Double Happiness is here!
Time of Update: 2021-04-23
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
-
Amgen's bispecific antibody AMG 570 gets clinical approval in China
Time of Update: 2021-04-23
Studies have found that in patients with autoimmune diseases such as systemic lupus erythematosus, the expression level of ICOS on T cells is elevated.
AMG 570 is a bispecific antibody developed by Amgen that can target BAFF and ICOSL at the same time.
-
110 pharmaceutical companies posted their first quarter transcripts!
Time of Update: 2021-04-23
Three companies including Intech Healthcare and Daan Gene have net profits of over 1 billion yuan; 500 million to 1 billion yuan are Changchun High-tech, Yiling Pharmaceutical, 7 companies including China Resources Sanjiu and Harbin Sanlian; 52 companies including Kelun Pharmaceutical, Haisco and Zuoli Pharmaceutical have doubled, and Hotview Bio has soared 1,000 times, becoming the "pre-increasing king" of performance; Qianhong Pharmaceutical, 18 companies including Jinling Pharmaceutical turned losses into profits.
-
To prepare for the fifth batch of national procurement, nine major pieces of information that companies must collect!
Time of Update: 2021-04-23
cn/news/yyzb/" target="_blank">。 ，，。 No matter what kind of response strategy an enterprise adopts, its foundation is to obtain accurate intelligence, especially information that is essential for making decisions.
-
The use rate of essential medicines is less than 70%, which affects the salary of primary doctors
Time of Update: 2021-04-23
According to a doctor at the grassroots level, the following problems are common in the use of medicine at the grassroots level:① The price of basic medicines in primary medical institutions is inflated and continues to rise, some even doubled, even more expensive than outside pharmacies.
-
Pfizer and Moderna refuse to cooperate with Johnson & Johnson on coagulation of the new crown vaccine
Time of Update: 2021-04-23
Compile Ke KeAccording to a recent report by the Wall Street Journal, Johnson & Johnson contacted Pfizer, Moderna and AstraZeneca to ask them to investigate the coagulation problem caused by the COVID-19 vaccine and "express opinions on safety issues.
-
The fifth batch of national centralized drug procurement started the inclusion of multiple 1 billion-level large varieties
Time of Update: 2021-04-23
It is reported that this centralized procurement may involve 60 varieties and 207 product specifications, including tumor chemotherapy drugs, digestive preparations, antibiotics, inhalation preparations, contrast agents, diabetes drugs, ophthalmology-related drugs, antiviral drugs, etc.
-
"Decentralization, management and service" reform of outpatient fee settlement and other matters are expected to be handled across provinces during the year
Time of Update: 2021-04-23
cn/" target="_blank"> and regulations Regarding the reform of “delegation, regulation, and service” in investment approval, the National Development and Reform Commission will organize and carry out special supervision of administrative law enforcement in the investment field, and guide local governments to accelerate the implementation of the commitment system for enterprise investment projects.
